Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R,R)-Tramadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 13/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 6/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,R)-Tramadol SCHEMBL14579837 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7464 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL12831358 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL6543836 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL1593740 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL3265792 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL5318670 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL11984200 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL730723 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL57496 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1135357-B1 | PROCESS FOR THE RESOLUTION OF TRAMADOL | ARAKIS LTD (GB) | 2003-10-29 | — | — | EP | claimed |
| US-6323368-B1 | RESOLVING RACEMIC TRAMADOL BY CLASSICAL SALT RESOLUTION USING A SUBSTANTIALLY SINGLE ENANTIOMER OF O,O-DI-P-TOLUOYLTARTARIC ACID AS A RESOLVING AGENT | DARWIN DISCOVERY, LTD. (GB) | 2001-11-27 | — | — | US | claimed |
| EP-1135357-A1 | PROCESS FOR THE RESOLUTION OF TRAMADOL | Darwin Discovery Limited (GB) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032554-A1 | PROCESS FOR THE RESOLUTION OF TRAMADOL | DARWIN DISCOVERY LIMITED (GB) | 2000-06-08 | — | — | WO | claimed |
| US-10781163-B2 | Process for preparation of O-Desmethyltramadol and salts thereof | R L FINECHEM PRIVATE LIMITED (IN) | 2020-09-22 | — | — | US | disclosed |
| US-20200231536-A1 | A PROCESS FOR PREPARATION OF O-DESMETHYLTRAMADOL AND SALTS THEREOF | R L FINECHEM PRIVATE LIMITED (IN) | 2020-07-23 | — | — | US | disclosed |
| WO-2019053494-A1 | A PROCESS FOR PREPARATION OF O-DESMETHYLTRAMADOL AND SALTS THEREOF | R L FINE CHEM PRIVATE LIMITED (IN) | 2019-03-21 | — | — | WO | disclosed |
| EP-2486921-A1 | Reducing Side Effects of Tramadol | DMI Biosciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2114147-B1 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES INC (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2120570-B1 | TREATMENT OF COMORBID PREMATURE EJACULATION AND ERECTILE DYSFUNCTION | DMI BIOSCIENCES INC (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2012036800-A3 | ELECTROSURGICAL TISSUE SEALING AUGMENTED WITH A SEAL-ENHANCING COMPOSITION | AESCULAP AG (DE) | 2012-05-10 | — | — | WO | disclosed |
| US-8158147-B2 | Delay or sustained release; encapsulated in film forming polymer; analgesics | VALEANT INTERNATIONAL (BARBADOS) SRL (BB) | 2012-04-17 | — | — | US | disclosed |
| US-6169205-B1 | Process for the purification of (RR,SS)-2-(dimethylamino) methyl-1-(3-methoxyphenyl)-cyclohexanol from (RS,SR)-2-(dimethylamino)methyl-1-(3-methoxyphenyl) cyclohexanol | DIPHARMA S.P.A. (IT) | 2001-01-02 | — | — | US | disclosed |
| EP-1005861-A1 | REMEDIES FOR FREQUENT URINATION AND URINARY INCONTINENCE | Nippon Shinyaku Co., Ltd. (JP) | 2000-06-07 | — | — | EP | disclosed |
| EP-0946161-A1 | SUSTAINED RELEASE PHARMACEUTICAL TABLETS WITH TRAMADOL BASE AND THEIR PREPARATION | THERABEL RESEARCH SA/NV (BE) | 1999-10-06 | — | — | EP | disclosed |
| EP-0940385-A1 | Process for the separation of the (RR,SS)-2-(dimethylamino)methyl-1-(3-methoxyphenyl)-cyclohexanol isomer from the (RS,SR) isomer by selective precipitation | Dinamite Dipharma S.p.A. (IT) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998026772-A1 | SUSTAINED RELEASE PHARMACEUTICAL TABLETS WITH TRAMADOL BASE AND THEIR PREPARATION | THERABEL RESEARCH S.A./N.V. (BE) | 1998-06-25 | — | — | WO | disclosed |
| EP-0534628-B1 | Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone, and their use | MCNEILAB INC (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5468744-A | Analgesics | MCNEIL LAB, INC. (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0534628-A1 | Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone, and their use | MCNEILAB, INC. (US) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231536-A1 | A PROCESS FOR PREPARATION OF O-DESMETHYLTRAMADOL AND SALTS THEREOF | CYP3A7, TET1, CYP3A4 | OPRM1 84/4885SLC6A2 109/4885SLC6A4 123/4885 |
| US-10781163-B2 | Process for preparation of O-Desmethyltramadol and salts thereof | TET1, TET2, TET3 | OPRM1 144/4885SLC6A2 151/4885SLC6A4 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.